A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Clinical trial NCT04194944 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04194944
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-17
- Primary completion
- 2023-05-01
- Enrollment
- 261
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.